Topic: Genzyme Corporation
PARIS (Reuters) - French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme, allowing it to begin merging the U.S. biotech firm into its business and add rare diseases to its growth areas.Sanofi said 84.6 percent of Genzyme's common stock had ...
NEW YORK (Reuters) - Genzyme Corp Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final -- and stands to earn considerably more should Genzyme's multiple sclerosis ...
PARIS (Reuters) - French drugmaker Sanofi-Aventis has agreed to buy Genzyme Corp for $20.1 billion in cash, plus payments tied to the success of the company's drugs, the companies said on Wednesday.Sanofi will pay $74 a share in cash and a contingent ...
BOSTON (Reuters) - Sanofi-Aventis SA has agreed in principle to acquire Genzyme Corp for $19.2 billion in cash plus future payments based on the performance of an experimental Genzyme drug, according to two sources with knowledge of the talks.Under the agreement, Genzyme ...
PHILADELPHIA (Reuters) - Sanofi-Aventis has completed a review of the financial books and operations of takeover target Genzyme Corp , but the two sides continue to discuss a final price for a potential deal, according to The Wall Street Journal.Sanofi did not ...
PARIS (Reuters) - French drugmaker Sanofi-Aventis reported progress in talks to buy U.S. biotech firm as it predicted 5-10 percent lower earnings this year."As we announced about 10 days ago, we have signed a confidentiality agreement with Genzyme," Chief Executive Chris Viehbacher ...
NEW YORK (Reuters) - France's Sanofi-Aventis may raise its bid for U.S. biotech Genzyme Corp to about $76 or $77 per share, including a potential future payout based on the performance of an experimental drug, Bloomberg reported on Tuesday.Citing people with knowledge ...
NEW YORK (Reuters) - U.S. biotechnology company Genzyme Corp and Sanofi-Aventis have executed a nondisclosure agreement, effectively giving the French company the ability to examine Genzyme's books as they continue talks on a possible merger.While the two companies previously disclosed they are ...
PARIS/LONDON (Reuters) - Genzyme Corp shares rose more than 3 percent on Monday after French drugmaker Sanofi-Aventis confirmed the companies were in direct talks about a takeover deal.Sanofi, whose shares slipped 1.4 percent, said late on Sunday that representatives from both companies ...
LONDON (Reuters) - French drugmaker Sanofi Aventis SA said on Sunday it was in discussions with U.S. bid target Genzyme Corp over ways to value a key Genzyme drug, in a sign the two sides are moving closer to a deal.Discussions over ...
From Around the Web
Video Gallery
-
BlackRock Will Replace Genzyme Corp In ...
BlackRock (NYSE:BLK) will replace Genzyme Corp. (NASDAQ:GENZ) in ...2011-03-30 -
Founders' Day 2011- John Crowley's ...
John F. Crowley is chairman and CEO of Amicus Therapeutics ...2011-10-13 -
Dane Chenery Show Guest Miss Massachusetts ...
FOR IMMEDIATE RELEASE Contact: The Dane Chenery Show Contact Person ...2011-10-01
